

Sunil R Lakhani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8080919/publications.pdf>

Version: 2024-02-01

172
papers

28,699
citations

15504

65
h-index

5679

162
g-index

177
all docs

177
docs citations

177
times ranked

40809
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
2	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016, 534, 47-54.	27.8	1,760
3	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , 2012, 486, 400-404.	27.8	1,535
4	Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. <i>Nature</i> , 2015, 527, 100-104.	27.8	966
5	The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in <i>BRCA1</i> and <i>BRCA2</i> . <i>Journal of Clinical Oncology</i> , 2002, 20, 2310-2318.	1.6	770
6	HRDetect is a predictor of <i>BRCA1</i> and <i>BRCA2</i> deficiency based on mutational signatures. <i>Nature Medicine</i> , 2017, 23, 517-525.	30.7	769
7	Identification of the familial cylindromatosis tumour-suppressor gene. <i>Nature Genetics</i> , 2000, 25, 160-165.	21.4	640
8	Prediction of <i>BRCA1</i> Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. <i>Clinical Cancer Research</i> , 2005, 11, 5175-5180.	7.0	577
9	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011, 24, 157-167.	5.5	545
10	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
11	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. <i>Journal of Clinical Oncology</i> , 2005, 23, 4152-4161.	1.6	479
12	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	4.3	469
13	Molecular evolution of breast cancer. <i>Journal of Pathology</i> , 2005, 205, 248-254.	4.5	442
14	Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer. <i>Cancer Research</i> , 2005, 65, 7591-7595.	0.9	429
15	The 2019 World Health Organization classification of tumours of the breast. <i>Histopathology</i> , 2020, 77, 181-185.	2.9	395
16	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251-1254.	12.6	348
17	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016, 68, 5-21.	2.9	329
18	SNORD-host RNA <i>Zfas1</i> is a regulator of mammary development and a potential marker for breast cancer. <i>Rna</i> , 2011, 17, 878-891.	3.5	321

#	ARTICLE	IF	CITATIONS
19	A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. <i>Nature Genetics</i> , 2005, 37, 590-592.	21.4	318
20	Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 169-180.	10.7	316
21	Diagnosis of breast cancer using elastic-scattering spectroscopy: preliminary clinical results. <i>Journal of Biomedical Optics</i> , 2000, 5, 221.	2.6	279
22	Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. <i>Breast Cancer Research</i> , 2007, 9, R4.	5.0	260
23	Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?. <i>American Journal of Surgical Pathology</i> , 2005, 29, 734-746.	3.7	256
24	<i>FGFR1</i> Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 6652-6662.	7.0	256
25	The topography of mutational processes in breast cancer genomes. <i>Nature Communications</i> , 2016, 7, 11383.	12.8	235
26	Expression Profiling of Purified Normal Human Luminal and Myoepithelial Breast Cells. <i>Cancer Research</i> , 2004, 64, 3037-3045.	0.9	233
27	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	5.5	230
28	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	27.8	229
29	Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers. <i>Clinical Cancer Research</i> , 2004, 10, 2473-2481.	7.0	224
30	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. <i>American Journal of Human Genetics</i> , 2016, 98, 830-842.	6.2	201
31	Typical medullary breast carcinomas have a basal/myoepithelial phenotype. <i>Journal of Pathology</i> , 2005, 207, 260-268.	4.5	198
32	Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. <i>Journal of Pathology</i> , 2005, 207, 1-13.	4.5	172
33	Metastatic progression of breast cancer: insights from 50 years of autopsies. <i>Journal of Pathology</i> , 2014, 232, 23-31.	4.5	161
34	Genetic and Histopathologic Evaluation of <i>BRCA1</i> and <i>BRCA2</i> DNA Sequence Variants of Unknown Clinical Significance. <i>Cancer Research</i> , 2006, 66, 2019-2027.	0.9	153
35	cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. <i>Oncogene</i> , 2003, 22, 2680-2688.	5.9	152
36	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142

#	ARTICLE	IF	CITATIONS
37	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013, 37, e1-e11.	3.7	137
38	Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes. <i>Clinical Cancer Research</i> , 2004, 10, 5988-5997.	7.0	135
39	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. <i>Breast Cancer Research</i> , 2005, 7, R1028-35.	5.0	134
40	The transition from hyperplasia to invasive carcinoma of the breast. , 1999, 187, 272-278.		128
41	Microarray and histopathological analysis of tumours: the future and the past?. <i>Nature Reviews Cancer</i> , 2001, 1, 151-157.	28.4	127
42	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R46.	5.0	122
43	X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3311-3314.	7.1	121
44	Breast cancer stem cells: treatment resistance and therapeutic opportunities. <i>Carcinogenesis</i> , 2011, 32, 650-658.	2.8	120
45	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	12.8	119
46	Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 153-165.	2.5	111
47	Loss of heterozygosity in ductal carcinoma in situ of the breast. <i>Journal of Pathology</i> , 1995, 175, 195-201.	4.5	110
48	The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. <i>Journal of Pathology</i> , 2002, 196, 437-444.	4.5	110
49	The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. <i>Breast Cancer Research</i> , 2003, 5, 258-62.	5.0	106
50	Reading Protocol for Dynamic Contrast-enhanced MR Images of the Breast: Sensitivity and Specificity Analysis. <i>Radiology</i> , 2005, 236, 779-788.	7.3	99
51	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. <i>Journal of Pathology</i> , 2015, 237, 363-378.	4.5	98
52	The mammary myoepithelial cell - Cinderella or ugly sister?. <i>Breast Cancer Research</i> , 2000, 3, 1-4.	5.0	97
53	CT-X antigen expression in human breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 13493-13498.	7.1	92
54	Subtypes of familial breast tumours revealed by expression and copy number profiling. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 661-677.	2.5	86

#	ARTICLE	IF	CITATIONS
55	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. <i>Human Mutation</i> , 2010, 31, E1484-E1505.	2.5	86
56	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85
57	The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? <i>European Journal of Cancer</i> , 2006, 42, 2205-2211.	2.8	81
58	Molecular Analysis of Phyllodes Tumors Reveals Distinct Changes in the Epithelial and Stromal Components. <i>American Journal of Pathology</i> , 2000, 156, 1093-1098.	3.8	80
59	DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation Status. <i>American Journal of Human Genetics</i> , 2010, 86, 420-433.	6.2	80
60	Rad51 supports triple negative breast cancer metastasis. <i>Oncotarget</i> , 2014, 5, 3261-3272.	1.8	80
61	Molecular Cytogenetic Comparison of Apocrine Hyperplasia and Apocrine Carcinoma of the Breast. <i>American Journal of Pathology</i> , 2001, 158, 207-214.	3.8	79
62	Molecular Evidence for Progression of Microglandular Adenosis (MGA) to Invasive Carcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 496-504.	3.7	77
63	A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. <i>Nature Genetics</i> , 2017, 49, 341-348.	21.4	75
64	Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. <i>Journal of Pathology</i> , 2019, 247, 214-227.	4.5	73
65	Clinical Classification of <i>BRCA1</i> and <i>BRCA2</i> DNA Sequence Variants: The Value of Cytokeratin Profiles and Evolutionary Analysis—A Report From the ConFab Investigators. <i>Journal of Clinical Oncology</i> , 2008, 26, 1657-1663.	1.6	72
66	BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. <i>Oncogene</i> , 2003, 22, 5572-5578.	5.9	71
67	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	5.5	69
68	Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. <i>Breast Cancer Research</i> , 2010, 12, R51.	5.0	68
69	Distribution and significance of 14-3-3 β , a novel myoepithelial marker, in normal, benign, and malignant breast tissue. <i>Journal of Pathology</i> , 2004, 202, 274-285.	4.5	67
70	Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor. <i>Journal of Nuclear Medicine</i> , 2013, 54, 913-921.	5.0	66
71	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	64
72	Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. <i>Breast Cancer Research</i> , 2021, 23, 6.	5.0	64

#	ARTICLE	IF	CITATIONS
73	Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. <i>Journal of Pathology</i> , 2010, 221, 452-461.	4.5	62
74	Incorporating tumour pathology information into breast cancer risk prediction algorithms. <i>Breast Cancer Research</i> , 2010, 12, R28.	5.0	62
75	Comparative Genomic Hybridization Analysis of Myoepithelial Carcinoma of the Breast. <i>Laboratory Investigation</i> , 2000, 80, 831-836.	3.7	60
76	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. <i>Oncotarget</i> , 2015, 6, 3932-3946.	1.8	60
77	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. <i>Breast Cancer Research</i> , 2007, 9, R82.	5.0	58
78	The cancer genetics and pathology of male breast cancer. <i>Histopathology</i> , 2016, 68, 110-118.	2.9	51
79	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017, 30, 952-963.	5.5	50
80	ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. <i>Nature Communications</i> , 2015, 6, 6548.	12.8	49
81	Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. <i>Future Oncology</i> , 2009, 5, 233-243.	2.4	48
82	Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. <i>Oncotarget</i> , 2014, 5, 3145-3158.	1.8	42
83	Malignant adenomyoepithelioma of the breast metastasizing to the liver. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 442, 504-506.	2.8	40
84	Comparative genomic hybridization analysis of bilateral hyperplasia of usual type of the breast. <i>Journal of Pathology</i> , 2003, 199, 152-156.	4.5	40
85	Proliferation and differentiation in the human breast during pregnancy. <i>Differentiation</i> , 2000, 66, 106-115.	1.9	38
86	Expression of <scp>MAGE</scp>A and <scp>NY</scp>-<scp>ESO</scp>1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. <i>Histopathology</i> , 2018, 73, 68-80.	2.9	34
87	DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 555-565.	2.5	33
88	Phenotype-Genotype Correlation in Familial Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 27-40.	2.7	31
89	Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. <i>Journal of Pathology</i> , 2018, 244, 460-468.	4.5	31
90	Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 25-39.	3.0	31

#	ARTICLE	IF	CITATIONS
91	In-situ lobular neoplasia: time for an awakening. <i>Lancet, The</i> , 2003, 361, 96.	13.7	30
92	Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype. <i>Journal of Pathology</i> , 2004, 204, 147-152.	4.5	29
93	Evaluation of a Prospective Scoring System Designed for a Multicenter Breast MR Imaging Screening Study. <i>Radiology</i> , 2006, 239, 677-685.	7.3	29
94	LobSig is a multigene predictor of outcome in invasive lobular carcinoma. <i>Npj Breast Cancer</i> , 2019, 5, 18.	5.2	28
95	Myoepithelial Cells: Pathology, Cell Separation and Markers of Myoepithelial Differentiation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 273-280.	2.7	27
96	Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 289-301.	2.5	27
97	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 75-104.	1.6	27
98	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. <i>PLoS ONE</i> , 2015, 10, e0125232.	2.5	27
99	Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. <i>British Journal of Cancer</i> , 2020, 123, 1665-1672.	6.4	26
100	Progesterone receptor-positive eruptive syringoma associated with diabetes. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, S103-S104.	1.2	25
101	TGF β 2 isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. <i>BMC Cancer</i> , 2015, 15, 1010.	2.6	25
102	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018, 72, 1075-1083.	2.9	25
103	Diff-Quik Cytology Smears from Endobronchial Ultrasound Transbronchial Needle Aspiration Lymph Node Specimens as a Source of DNA for Next-Generation Sequencing Instead of Cell Blocks. <i>Respiration</i> , 2019, 97, 525-539.	2.6	25
104	Recent advances in breast cancer research impacting clinical diagnostic practice. <i>Journal of Pathology</i> , 2019, 247, 552-562.	4.5	24
105	Profiling familial breast cancer. <i>Nature Medicine</i> , 2001, 7, 408-410.	30.7	23
106	Molecular and morphological analysis of adenoid cystic carcinoma of the breast with synchronous tubular adenosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 107-114.	2.8	23
107	Environmental factors in breast cancer invasion: a mathematical modelling review. <i>Pathology</i> , 2017, 49, 172-180.	0.6	23
108	American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications. <i>Annals of Diagnostic Pathology</i> , 2020, 45, 151481.	1.3	23

#	ARTICLE	IF	CITATIONS
109	Molecular classification of breast cancer: is it time to pack up our microscopes?. Pathology, 2011, 43, 1-8.	0.6	22
110	Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment. International Journal of Molecular Sciences, 2019, 20, 2524.	4.1	22
111	Non-coding RNAs underlie genetic predisposition to breast cancer. Genome Biology, 2020, 21, 7.	8.8	21
112	The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence. British Journal of Cancer, 2021, 124, 156-160.	6.4	21
113	Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019, 5, .	5.0	21
114	Breast Cancer Brain Metastases: Clonal Evolution in Clinical Context. International Journal of Molecular Sciences, 2017, 18, 152.	4.1	20
115	Can the stroma provide the clue to the cellular basis for mammographic density?. Breast Cancer Research, 2003, 5, 225-7.	5.0	19
116	Using whole-genome sequencing data to derive the homologous recombination deficiency scores. Npj Breast Cancer, 2020, 6, 33.	5.2	19
117	Can magnetic-resonance imaging help elucidate natural history of breast cancer multicentricity?. Lancet, The, 1998, 351, 801-802.	13.7	18
118	Current and future approach to the pathologist's assessment for targeted therapy in breast cancer. Pathology, 2009, 41, 89-99.	0.6	18
119	Id Proteins Promote a Cancer Stem Cell Phenotype in Mouse Models of Triple Negative Breast Cancer via Negative Regulation of Robo1. Frontiers in Cell and Developmental Biology, 2020, 8, 552.	3.7	18
120	How diagnosis with microarrays can help cancer patients. Nature, 2000, 404, 921-921.	27.8	17
121	Omics Approaches in Breast Cancer Research and Clinical Practice. Advances in Anatomic Pathology, 2016, 23, 356-367.	4.3	17
122	Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases. International Journal of Molecular Sciences, 2019, 20, 1280.	4.1	17
123	Multifactorial Likelihood Assessment of BRCA1 and BRCA2 Missense Variants Confirms That BRCA1:c.122A>G(p.His41Arg) Is a Pathogenic Mutation. PLoS ONE, 2014, 9, e86836.	2.5	17
124	A test of performance of breast MRI interpretation in a multicentre screening study. Magnetic Resonance Imaging, 2006, 24, 917-929.	1.8	16
125	Digital spatial profiling application in breast cancer: a user's perspective. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 885-890.	2.8	16
126	Mutation analysis of five candidate genes in familial breast cancer. Breast Cancer Research and Treatment, 2007, 105, 377-389.	2.5	14

#	ARTICLE	IF	CITATIONS
127	Next-Generation Sequencing of Endobronchial Ultrasound Transbronchial Needle Aspiration Specimens in Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 388-391.	5.6	14
128	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. <i>Cancers</i> , 2020, 12, 848.	3.7	14
129	Putting the Brakes on Cylindromatosis?. <i>New England Journal of Medicine</i> , 2004, 350, 187-188.	27.0	13
130	Fibroadenoma and intraduct papillomaâ€”a common pathogenesis?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 455, 271-275.	2.8	13
131	Lobular carcinoma in situ: diagnostic criteria and molecular correlates. <i>Modern Pathology</i> , 2021, 34, 8-14.	5.5	13
132	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021, 78, 759-771.	2.9	13
133	The Genomic Landscape of Lobular Breast Cancer. <i>Cancers</i> , 2021, 13, 1950.	3.7	13
134	The Brisbane Breast Bank. <i>Open Journal of Bioresources</i> , 2018, 5, .	1.5	13
135	MR imaging of the skin and nipple of the breast: differentiation between tumour recurrence and post-treatment change. <i>European Radiology</i> , 2001, 11, 1651-1658.	4.5	12
136	Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants displaying in vitro splicing results of equivocal clinical significance. <i>Human Mutation</i> , 2010, 31, E1141-E1145.	2.5	12
137	Spatial profiling technologies and applications for brain cancers. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 323-332.	3.1	12
138	Introduction: The Role of Myoepithelial Cells in Integration of Form and Function in the Mammary Gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2005, 10, 197-198.	2.7	11
139	ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. <i>Pathology</i> , 2019, 51, 345-348.	0.6	11
140	Clinicopathologic significance of nuclear HER4 and phospho-YAP(S ¹²⁷) in human breast cancers and matching brain metastases. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094625.	3.2	11
141	Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer. <i>Life Science Alliance</i> , 2020, 3, e201900562.	2.8	11
142	Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 257.	3.7	11
143	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 57.	5.2	11
144	High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations. <i>Breast Cancer Research</i> , 2016, 18, 18.	5.0	9

#	ARTICLE	IF	CITATIONS
145	Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content. BMC Cancer, 2022, 22, 85.	2.6	9
146	Targeted disruption of Brca1 in restricted compartments of the mouse mammary epithelia. Breast Cancer Research and Treatment, 2008, 112, 237-241.	2.5	8
147	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Research, 2020, 22, 63.	5.0	8
148	Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?. Breast Cancer Research, 2010, 12, 104.	5.0	7
149	Tumor Heterogeneity in a Follicular Carcinoma of Thyroid: a Study by Comparative Genomic Hybridization. Endocrine Pathology, 2011, 22, 103-107.	9.0	7
150	An Update on the Molecular Pathology of Metaplastic Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 161-170.	1.8	7
151	N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. BMC Cancer, 2022, 22, 334.	2.6	7
152	In Situ Carcinomaâ€”Can We Predict which Patient Will Come Back with a Recurrence?. Cancer Cell, 2007, 12, 409-411.	16.8	6
153	Application of molecular findings to the diagnosis and management of breast disease: recent advances and challenges. Human Pathology, 2011, 42, 153-165.	2.0	6
154	Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology, 2021, 10, 425.	2.8	6
155	THE EXPRESSION PATTERNS OF INTEGRIN SUBUNITS ON HUMAN BREAST TISSUES OBTAINED DURING PREGNANCY. Cell Biology International, 2002, 26, 593-598.	3.0	5
156	Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Research and Treatment, 2018, 170, 179-188.	2.5	5
157	Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development. Cancers, 2021, 13, 1762.	3.7	5
158	Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4651.	3.7	5
159	Altered Calcium Influx Pathways in Cancer-Associated Fibroblasts. Biomedicines, 2021, 9, 680.	3.2	4
160	Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. Cancers, 2022, 14, 533.	3.7	4
161	The diagnosis and management of pre-invasive breast disease â€” current challenges, future hopes. Breast Cancer Research, 2003, 5, 248-9.	5.0	3
162	Extramedullary megakaryoblastic leukaemia with massive generalised infiltration. Pathology, 2011, 43, 517-519.	0.6	2

#	ARTICLE	IF	CITATIONS
163	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. JAMA Network Open, 2020, 3, e209486.	5.9	2
164	Whatâ€™s in a cancer syndrome? Genes, phenotype and pathology. Pathology, 2008, 40, 247-259.	0.6	1
165	Flipping Pathology: Our Experience at an Australian Medical School. Medical Science Educator, 2017, 27, 409-415.	1.5	1
166	A Molecular and Morphological Deep-Dive Into Metaplastic Breast Cancers. Cancer Informatics, 2019, 18, 117693511985015.	1.9	1
167	Phenotypic drift in metastatic progression of breast cancer: A case report with histologically heterogeneous lesions that are clonally related. Clinical Case Reports (discontinued), 2020, 8, 2725-2731.	0.5	1
168	Genetic alterations in â€˜normalâ€™ luminal and myoepithelial cells of the breast. Journal of Pathology, 1999, 189, 496-503.	4.5	1
169	Genetic Alterations in Normal and Malignant Breast Tissue. , 2010, , 53-66.		1
170	Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastasesâ€™From Biology to Clinical Utility. Diseases (Basel, Switzerland), 2022, 10, 11.	2.5	1
171	Current topics in breast pathology: expert perspectives. Pathology, 2017, 49, 109-110.	0.6	0
172	Lobular Carcinoma in Situ. , 2010, , 181-199.		0